ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0922

Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Sex Correlates
Abstract Number: 1380

Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Abstract Number: 0784

Physical Activity and Exercise Therapy Reduce the Transition from Acute to Chronic Low Back Pain in the Community
Abstract Number: 2426

Physical Activity Patterns and Health-Related Quality of Life in Middle-Aged and Older Adults with Systemic Lupus Erythematosus
Abstract Number: 1341

Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures
Abstract Number: 1640

Physical Function and Performance in SLE: A Comparison of Two Population-Based Cohorts
Abstract Number: 2308

Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
Abstract Number: 2189

Physician Practices and Perspectives in the Diagnosis and Management of Fibromyalgia: A US Chart Review Study
Abstract Number: 0570

Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Abstract Number: 0466

Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
Abstract Number: 1990

Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Abstract Number: 2215

Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes
Abstract Number: 1160

Plasma Adenosine Deaminase 2 as a Potential Disease Activity Biomarker for Sarcoidosis
Abstract Number: 1211

Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
Abstract Number: 1307

Plasma levels of monounsaturated fatty acids (MUFAs) positively correlate with disease activity in patients with rheumatoid arthritis (RA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].